ClinicalTrials.gg
CompletedNCT03873038Updated Jun 6, 2024Results posted

Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)

A Phase 1 interventional study of MK-2060 and Placebo in Renal Dialysis and Kidney Failure, Chronic, sponsored by Merck Sharp & Dohme LLC. Completed at 3 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-06-06.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Kidney Failure, Chronic by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Kidney Failure, Chronic · Merck & Co., Inc.

Enrollment
3rd of 12
38 · median 18
Started
2019
the only one that year
Phase 1
10 of 12
none open now
Registered
5th of 12
by date

Among the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc, this one is the 3rd largest by enrollment, is the only one that started in 2019, is one of 10 in phase 1, and was the 5th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

None of the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc is open now. The open studies under Kidney Failure, Chronic, anywhere →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-2060 after intravenous (IV) administration of single and multiple doses in older adult participants with end-stage renal disease (ESRD) on hemodialysis (HD).

03

Conditions studied

  • Renal Dialysis
  • Kidney Failure, Chronic
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, of non-child bearing potential (WONCBP) age ≥40 and ≤80 years for Part 1 and ≥18 and ≤80 years for Part 2.
  • End-stage renal disease (ESRD) maintained on stable outpatient hemodialysis (HD) regimen, using an established (> 3 months) and normally functioning, regular flow, uninfected mature arteriovenous (AV) fistula or AV graft and skin consistent with standard chronic HD access injuries, and HD stability defined as ([K, dialyzer clearance, multiplied by t, time, divided by V, patient's total body water] Kt/V) ≥ 1.2 within 3 months prior to dosing at a healthcare center for > 3 months from dosing.
  • On HD regimen at least 3 times per week for a minimum of 3 hours per dialysis session, using a complication-free well-maintained AV fistula or AV graft, expected and plan to continue this throughout and for at least 3 months beyond the study.
  • Has a (BMI) ≥ 18 and ≤ 45 kg/m\^2, BMI = weight (kg)/height (m)\^2.
  • Baseline health is judged to be stable based on medical history, physical examination, vital sign measurements and (ECG) performed prior to randomization.
  • Liver function test (serum [ALT] and aspartate aminotransferase [AST]) must be equal to or below 1.5X (ULN) and deemed not by both the investigator and the Sponsor.
  • use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies by agreeing to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a woman of (WOCBP) who is not currently pregnant. Also, men with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile-vaginal penetration.
  • Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies in that a female participant is eligible to participate if she is not pregnant or breastfeeding and she is not a WOCBP in that she is a female without menses for at least 1 year OR is a surgically sterile female, post hysterectomy, bilateral salpingectomy, oophorectomy or tubal ligation.

Exclusion criteria

Exclusion Criteria:

  • Has a history of any concomitant disease or condition (including treatment for such conditions) or diseases whose current condition is considered clinically unstable that, in the opinion of the investigator, could either interfere with the study drug, compromise interpretation of study data, or pose an unacceptable risk. Participants with a remote history of uncomplicated medical events (e.g., uncomplicated kidney stones, as defined as spontaneous passage and no recurrence in the last 5 years, or childhood asthma) may be enrolled in the study at the discretion of the investigator.
  • Is mentally or legally incapacitated, has significant emotional problems at the time of prestudy (screening) visit or expected during the conduct of the study or has a history of clinically significant psychiatric disorder of the last 5 years. Participants who have had situational depression may be enrolled in the study at the discretion of the investigator.
  • Has a history of cancer (), including adenocarcinoma, with possible exceptions being participants with adequately treated non-melanomatous skin carcinoma; participants with other malignancies which have been successfully treated ≥10 years prior to the pretrial (screening) visit; or participants who, in the opinion of the trial investigator, are highly unlikely to sustain a recurrence for the duration of the trial.
  • Has blood coagulation test ( [aPTT], prothrombin time [PT]) ≥ 20 % outside of normal range on pretrial (screening), which are considered clinically significant by both the investigator and the sponsor.
  • Any other clinically significant abnormalities in laboratory test results at screening that would, in the opinion of the investigator, increase the participant's risk of participation, jeopardize complete participation in the study, or compromise interpretation of study data.
  • Has a history of deep vein thrombosis or pulmonary embolism. Has a history of vascular access thrombosis within 1 month prior to enrollment. Has a personal or family history of bleeding disorder.
  • Has a history of gastrointestinal (GI) bleeding, duodenal polyps or gastric ulcer in the last 5 years or severe hemorrhoidal bleed in last 3 months.
  • Has a history of or current frequent epistaxis within the last 3 months or active gingivitis.
  • Has ongoing anticoagulant therapy (warfarin, apixaban, dabigatran, rivaroxaban, edoxaban, betrixaban) or antiplatelet therapy (clopidogrel, prasugrel, ticagrelor, ticlopidine). Intradialytic heparin and aspirin are permitted.
  • At the time of screening or pre-dose, has planned significant dental procedures (including planned dental surgery), or other planned surgical procedures within duration of participation in the trial.
  • Is positive for surface antigen or human immunodeficiency viruses ().
  • Has had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the pre-study (screening) visits.
  • Has a history of significant multiple and/or severe allergies (e.g. food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerability (i.e. systemic allergic reaction) to prescription or non-prescription drugs or food.
  • Has a tattoo, scar, or other physical finding at the area of the infusion site that would interfere with infusion or a local tolerability assessment.
  • Has a history of receiving any human immunoglobulin preparation such as intravenous immunoglobulin (IVIG) or RhoGAM within the last year.
  • Has a history of receiving any biological therapy (including human blood products or monoclonal antibodies; excluding erythropoietin and insulin) within the last 3 months or 5 half-lives (whichever is longer), or vaccination within the last 1 month (exceptions include seasonal flu vaccine and pneumococcal vaccine within the last month; coronavirus disease 2019 [COVID-19] vaccine that is licensed and approved for emergency use and with the study intervention given 72 hours following vaccination or 48 hours prior to vaccination).
  • The exclusion criteria for is a heart rate \< 40 or > 110 beats per minute (bpm); corrected Q-T () interval > 500 minutes/second; any significant arrhythmia or conduction abnormality, (including but not specific to atrioventricular block [2nd degree or higher], Wolff Parkinson White syndrome [unless curative radio ablation therapy]), which, in the opinion of the investigator and sponsor, could interfere with the safety for the individual participant; and non-sustained or sustained ventricular tachycardia (> 2 consecutive ventricular ectopic beats at a rate of > 1.7/second).
  • Is unable to refrain from or anticipates the use of medication, including prescription and nonprescription drugs or herbal remedies beginning approximately 2 weeks prior to administration of the initial dose of study drug, throughout the study until the poststudy visit. Specific allowed and prohibited medications are provided in the protocol.
  • Has participated in another study within 4 weeks prior to sponsor's investigational drug (MK-2060/placebo) administration.
  • Has a blood pressure >190 mmHg systolic or >110 mmHg diastolic.
  • Consumes greater than 3 glasses of alcoholic beverages (1 glass is approximately equivalent to: beer 354 mL/12 ounces, wine 118 mL/4 ounces, or distilled spirits 29.5 mL/1 ounce) per day. Participants who consume 4 glasses of alcoholic beverages per day may be enrolled at the discretion of the investigator.
  • Consumes excessive amounts, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks, or other caffeinated beverages per day.
  • Is a regular user of any illicit drugs or has a history of drug (including alcohol) abuse within approximately 2 years. Participants must have a negative serum or saliva drug screen prior to randomization. Participants with a positive drug screen due to the use of physician prescribed medications (e.g., opioids, benzodiazepines, antidepressants) may be enrolled at the discretion of the investigator. In addition, participants with a positive tetrahydrocannabinol (THC) may be enrolled at the discretion of the investigator if the participants' THC use is under 4 times/month and the participants agree to not use during their study participation. Participants with positive THC on screening may have rechecks performed at the discretion of the investigator to ensure compliance with abstinence from THC use during study participation.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Part 1: Panel A- MK-2060 (8 mg)

    Participants will receive a single 8-mg dose of MK-2060 via intravenous (IV) infusion.

    Drug: MK-2060

  • Experimental
    Part 1: Panel B- MK-2060 (20 mg)

    Participants will receive a single 20-mg dose of MK-2060 via IV infusion.

    Drug: MK-2060

  • Experimental
    Part 1: Panel C- MK-2060 (40 mg)

    Participants will receive a single 40-mg dose of MK-2060 via IV infusion.

    Drug: MK-2060

  • Placebo comparator
    Part 1: Placebo

    Participants will receive a single dose of placebo via IV infusion.

    Drug: Placebo

  • Experimental
    Part 2: MK-2060 25-mg Loading/ 25-mg Maintenance

    Participants will receive three doses of up to 25 mg MK-2060 via IV infusion in the first week (Week 1), followed by a single dose of up to 25 mg MK-2060 via IV infusion weekly for 3 weeks (Weeks 2-4)

    Drug: MK-2060

  • Placebo comparator
    Part 2: Placebo

    Participants will receive three doses of placebo via IV infusion in the first week and then a single dose of placebo via IV infusion weekly for 3 weeks (Weeks 2-4)

    Drug: Placebo

Interventions

  • Part 1: Single doses (8 mg, 20 mg, or 40 mg) of MK-2060 will be administered via IV infusion on Day 1. Part 2: Three doses of 25 mg of MK- 2060 administered via IV infusion on Days 1, 3 and 5; Followed by single doses of 25 mg of MK-2060 administered via IV infusion on Days 8, 15, and 22.

  • DrugPlacebo

    Part 1: Single dose of placebo will be administered via IV infusion on Day 1. Part 2: Three doses of placebo administered via IV infusion on Days 1, 3 and 5; Followed by single doses of placebo administered via IV infusion on Days 8, 15, and 22.

06

What researchers measure

Primary outcomes

  1. Part 1: Percentage of Participants With Any Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants that experienced an AE was summarized.

    Time frame: Up to 164 days

  2. Part 2: Percentage of Participants With Any AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced an AE was summarized.

    Time frame: Up to 118 days

  3. Part 1: Percentage of Participants With Any Serious Adverse Event

    A serious adverse event (SAE) is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. The percentage of participants who experienced an SAE was summarized.

    Time frame: Up to 164 days

  4. Part 2: Percentage of Participants With Any SAE

    An SAE is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. The percentage of participants who experienced an SAE was summarized.

    Time frame: Up to 118 days

  5. Part 1: Percentage of Participants With a Systemic AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The solicited systemic AEs assessed included but not limited to fever, vital sign (VS) changes (tachycardia/hypotension), pruritis, urticarial (hives), lip swelling, angioedema, bronchospasm, stridor, hoarseness, and shortness of breath.

    Time frame: Up to 164 days

  6. Part 2: Percentage of Participants With a Systemic AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The solicited systemic AEs assessed included but not limited to fever, vital sign (VS) changes (tachycardia/hypotension), pruritis, urticarial (hives), lip swelling, angioedema, bronchospasm, stridor, hoarseness, and shortness of breath.

    Time frame: Up to 118 days

  7. Part 1: Percentage of Participants With an Injection-Site AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The solicited injection-site AEs assessed were pain, tenderness, erythema/redness, and induration/swelling.

    Time frame: Up to 164 days

  8. Part 2: Percentage of Participants With an Injection-Site AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The solicited injection-site AEs assessed were pain, tenderness, erythema/redness, and induration/swelling.

    Time frame: Up to 118 days

  9. Part 1: Percentage of Participants Discontinuing the Study Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants that discontinued the study due to an AE was summarized.

    Time frame: Up to 164 days

  10. Part 2: Percentage of Participants Discontinuing Study Drug Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants that had study drug discontinued regardless of study completion status was summarized.

    Time frame: Up to 4 weeks

Secondary outcomes

  1. Part 1: Area Under the Plasma Concentration-Time Curve of MK-2060 From 0 to Infinity (AUC0-inf)

    Plasma samples were collected at pre-specified time points post-dose and AUC0-inf was assessed.

    Time frame: Predose Day 1 and 1, 12, 24, 48, 52, 96, 168 hours postdose, then Days 12, 15, 22, 29, 60, 90, 120, 150

  2. Part 1: Area Under the Plasma Concentration-Time Curve of MK-2060 From Time 0 to 168 Hours (AUC0-168)

    Plasma samples were collected at pre-specified time points post-dose and AUC0-168 hours was assessed.

    Time frame: Predose Day 1 and 1, 12, 24, 48, 52, 96, 168 hours postdose

  3. Part 1: Maximum Observed Plasma Concentration (Cmax) of MK-2060

    Plasma samples were collected at pre-specified time points post-dose and Cmax was assessed.

    Time frame: Predose Day 1 and 1, 12, 24, 48, 52, 96, 168 hours postdose, then Days 12, 15, 22, 29, 60, 90, 120, 150

  4. Part 1: Plasma Concentration of MK-2060 at 168 Hours (C168)

    Plasma samples were collected at 168 hours post-dose and C168 was assessed.

    Time frame: 168 hours post dose

  5. Part 1: Time to Maximum Observed Plasma Drug Concentration (Tmax) of MK-2060

    Plasma samples were collected at pre-specified time points post-dose and Tmax was assessed.

    Time frame: Predose Day 1 and 1, 12, 24, 48, 52, 96, 168 hours postdose

  6. Part 1: Plasma Elimination Terminal Half-life (t ½) of MK-2060

    Plasma samples was collected at pre-specified time points post-dose and t ½ was assessed.

    Time frame: Predose Day 1 and 1, 12, 24, 48, 52, 96, 168 hours postdose

  7. Part 1: Plasma Clearance (CL) of MK-2060

    Plasma samples were collected at pre-specified time points post-dose and CL was assessed.

    Time frame: Predose Day 1 and 1, 12, 24, 48, 52, 96, 168 hours postdose

  8. Part 1: Plasma Volume of Distribution (Vz) of MK-2060

    Plasma samples were collected at pre-specified time points post-dose and Vz was assessed.

    Time frame: Predose Day 1 and 1, 12, 24, 48, 52, 96, 168 hours postdose

  9. Part 2: AUC0-168 of MK-2060

    Plasma samples were collected at pre-specified time points post-dose and AUC0-168 hours was assessed.

    Time frame: Up to 168 hours on Day 1 and Day 22

  10. Part 2: Cmax of MK-2060

    Plasma samples were collected at pre-specified time points post-dose and Cmax was assessed.

    Time frame: Day 1 and Day 22

  11. Part 2: C168 of MK-2060

    Plasma samples were collected at 168 hours post-dose and C168 was assessed.

    Time frame: 168 hours post dose on Days 1 and 22

  12. Part 2: Tmax of MK-2060

    Plasma samples were collected at pre-specified time points post-dose and Tmax was assessed.

    Time frame: Day 1 and Day 22

  13. Fold Change From Baseline in Activated Partial Thromboplastin Time (aPTT) of MK-2060: Part 1

    Plasma samples were collected at pre-specified time points post-dose and aPTT values were assessed. The fold change (Day 8/Baseline) at Day 8 was reported.

    Time frame: Baseline and 168 hours post-dose (Day 8)

  14. Fold Change From Baseline in aPTT of MK-2060: Part 2

    Plasma samples were collected at pre-specified time points post-dose and aPTT values were assessed. The fold change (Day 8/Baseline) at Day 8 was reported.

    Time frame: Baseline and Day 8

07

Results

Posted Jun 6, 2024

Participant flow

Male and Female of non-childbearing potential (WONCBP) participants with end-stage renal disease (ESRD) on hemodialysis (HD) between the ages of 18 and 80 years (ages ≥ 40 and ≤ 80 for Part 1 and ≥ 18 and ≤ 80 for Part 2) were enrolled in this study.

Part 1
Participant flow — Part 1
MilestonePart 1: Panel A- MK-2060 (8 mg)Part 1: Panel B- MK-2060 (20 mg)Part 1: Panel C- MK-2060 (40 mg)Part 1: PlaceboPart 2: MK-2060 25-mg Loading/ 25-mg MaintenancePart 2: Placebo
Started676500
Completed676500
Not completed000000
Part 2
Participant flow — Part 2
MilestonePart 1: Panel A- MK-2060 (8 mg)Part 1: Panel B- MK-2060 (20 mg)Part 1: Panel C- MK-2060 (40 mg)Part 1: PlaceboPart 2: MK-2060 25-mg Loading/ 25-mg MaintenancePart 2: Placebo
Started0000165
Completed0000154
Not completed000011
Withdrew: Withdrawal by subject000001
Withdrew: Unknon000010

Outcome measures

PrimaryPart 1: Percentage of Participants With Any Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants that experienced an AE was summarized.

Time frame:
Up to 164 days
Reported as:
Number · Percentage of Participants
Part 1: Percentage of Participants With Any Adverse Event (AE)
Percentage of ParticipantsPart 1: Panel A- MK-2060 (8 mg)Part 1: Panel B- MK-2060 (20 mg)Part 1: Panel A- MK-2060 (40 mg)Part 1: Placebo
Part 1: Percentage of Participants With Any Adverse Event (AE)16.757.166.760.0
PrimaryPart 2: Percentage of Participants With Any AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced an AE was summarized.

Time frame:
Up to 118 days
Reported as:
Number · Percentage of Participants
Part 2: Percentage of Participants With Any AE
Percentage of ParticipantsPart 2: MK-2060 25-mg Loading/ 25-mg MaintenancePart 2: Placebo
Part 2: Percentage of Participants With Any AE12.5100.0
PrimaryPart 1: Percentage of Participants With Any Serious Adverse Event

A serious adverse event (SAE) is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. The percentage of participants who experienced an SAE was summarized.

Time frame:
Up to 164 days
Reported as:
Number · Percentage of Participants
Part 1: Percentage of Participants With Any Serious Adverse Event
Percentage of ParticipantsPart 1: Panel A- MK-2060 (8 mg)Part 1: Panel B- MK-2060 (20 mg)Part 1: Panel A- MK-2060 (40 mg)Part 1: Placebo
Part 1: Percentage of Participants With Any Serious Adverse Event0.00.016.70.0
PrimaryPart 2: Percentage of Participants With Any SAE

An SAE is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. The percentage of participants who experienced an SAE was summarized.

Time frame:
Up to 118 days
Reported as:
Number · Percentage of Participants
Part 2: Percentage of Participants With Any SAE
Percentage of ParticipantsPart 2: MK-2060 25-mg Loading/ 25-mg MaintenancePart 2: Placebo
Part 2: Percentage of Participants With Any SAE6.360.0
PrimaryPart 1: Percentage of Participants With a Systemic AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The solicited systemic AEs assessed included but not limited to fever, vital sign (VS) changes (tachycardia/hypotension), pruritis, urticarial (hives), lip swelling, angioedema, bronchospasm, stridor, hoarseness, and shortness of breath.

Time frame:
Up to 164 days
Reported as:
Number · Percentage of Participants
Part 1: Percentage of Participants With a Systemic AE
Percentage of ParticipantsPart 1: Panel A- MK-2060 (8 mg)Part 1: Panel B- MK-2060 (20 mg)Part 1: Panel A- MK-2060 (40 mg)Part 1: Placebo
Part 1: Percentage of Participants With a Systemic AE0.00.00.00.0
PrimaryPart 2: Percentage of Participants With a Systemic AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The solicited systemic AEs assessed included but not limited to fever, vital sign (VS) changes (tachycardia/hypotension), pruritis, urticarial (hives), lip swelling, angioedema, bronchospasm, stridor, hoarseness, and shortness of breath.

Time frame:
Up to 118 days
Reported as:
Number · Percentage of Participants
Part 2: Percentage of Participants With a Systemic AE
Percentage of ParticipantsPart 2: MK-2060 25-mg Loading/ 25-mg MaintenancePart 2: Placebo
Part 2: Percentage of Participants With a Systemic AE0.00.0
PrimaryPart 1: Percentage of Participants With an Injection-Site AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The solicited injection-site AEs assessed were pain, tenderness, erythema/redness, and induration/swelling.

Time frame:
Up to 164 days
Reported as:
Number · Percentage of Participants
Part 1: Percentage of Participants With an Injection-Site AE
Percentage of ParticipantsPart 1: Panel A- MK-2060 (8 mg)Part 1: Panel B- MK-2060 (20 mg)Part 1: Panel A- MK-2060 (40 mg)Part 1: Placebo
Part 1: Percentage of Participants With an Injection-Site AE0.00.00.00.0
PrimaryPart 2: Percentage of Participants With an Injection-Site AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The solicited injection-site AEs assessed were pain, tenderness, erythema/redness, and induration/swelling.

Time frame:
Up to 118 days
Reported as:
Number · Percentage of Participants
Part 2: Percentage of Participants With an Injection-Site AE
Percentage of ParticipantsPart 2: MK-2060 25-mg Loading/ 25-mg MaintenancePart 2: Placebo
Part 2: Percentage of Participants With an Injection-Site AE0.00.0
PrimaryPart 1: Percentage of Participants Discontinuing the Study Due to an AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants that discontinued the study due to an AE was summarized.

Time frame:
Up to 164 days
Reported as:
Number · Percentage of Participants
Part 1: Percentage of Participants Discontinuing the Study Due to an AE
Percentage of ParticipantsPart 1: Panel A- MK-2060 (8 mg)Part 1: Panel B- MK-2060 (20 mg)Part 1: Panel A- MK-2060 (40 mg)Part 1: Placebo
Part 1: Percentage of Participants Discontinuing the Study Due to an AE0.00.00.00.0
PrimaryPart 2: Percentage of Participants Discontinuing Study Drug Due to an AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants that had study drug discontinued regardless of study completion status was summarized.

Time frame:
Up to 4 weeks
Reported as:
Number · Percentage of Participants
Part 2: Percentage of Participants Discontinuing Study Drug Due to an AE
Percentage of ParticipantsPart 2: MK-2060 25-mg Loading/ 25-mg MaintenancePart 2: Placebo
Part 2: Percentage of Participants Discontinuing Study Drug Due to an AE0.040.0
SecondaryPart 1: Area Under the Plasma Concentration-Time Curve of MK-2060 From 0 to Infinity (AUC0-inf)

Plasma samples were collected at pre-specified time points post-dose and AUC0-inf was assessed.

Time frame:
Predose Day 1 and 1, 12, 24, 48, 52, 96, 168 hours postdose, then Days 12, 15, 22, 29, 60, 90, 120, 150
Reported as:
Geometric mean · hr*nmol/Liter
Part 1: Area Under the Plasma Concentration-Time Curve of MK-2060 From 0 to Infinity (AUC0-inf)
hr*nmol/LiterPart 1: Panel A- MK-2060 (8 mg)Part 1: Panel B- MK-2060 (20 mg)Part 1: Panel A- MK-2060 (40 mg)
Part 1: Area Under the Plasma Concentration-Time Curve of MK-2060 From 0 to Infinity (AUC0-inf)4550 ± 61.26520 ± 63.415100 ± 31.7
Statistical analysis
  • Part 1: Panel A- MK-2060 (8 mg) · Gmr: 0.80 · 90% CI 0.54 to 1.18GMR=GM ESRD/GM Healthy
  • Part 1: Panel B- MK-2060 (20 mg) · Gmr: 0.53 · 90% CI 0.37 to 0.76GMR=GM ESRD/GM Healthy
  • Part 1: Panel A- MK-2060 (40 mg) · Gmr: 0.82 · 90% CI 0.55 to 1.21GMR=GM ESRD/GM Healthy
SecondaryPart 1: Area Under the Plasma Concentration-Time Curve of MK-2060 From Time 0 to 168 Hours (AUC0-168)

Plasma samples were collected at pre-specified time points post-dose and AUC0-168 hours was assessed.

Time frame:
Predose Day 1 and 1, 12, 24, 48, 52, 96, 168 hours postdose
Reported as:
Geometric mean · hr*nmol/Liter
Part 1: Area Under the Plasma Concentration-Time Curve of MK-2060 From Time 0 to 168 Hours (AUC0-168)
hr*nmol/LiterPart 1: Panel A- MK-2060 (8 mg)Part 1: Panel B- MK-2060 (20 mg)Part 1: Panel A- MK-2060 (40 mg)
Part 1: Area Under the Plasma Concentration-Time Curve of MK-2060 From Time 0 to 168 Hours (AUC0-168)1560 ± 32.52420 ± 47.04930 ± 26.8
Statistical analysis
  • Part 1: Panel A- MK-2060 (8 mg) · Gmr: 1.41 · 90% CI 1.07 to 1.85GMR=GM ESRD/GM Healthy
  • Part 1: Panel B- MK-2060 (20 mg) · Gmr: 0.86 · 90% CI 0.67 to 1.11GMR=GM ESRD/GM Healthy
  • Part 1: Panel A- MK-2060 (40 mg) · Gmr: 0.82 · 90% CI 0.62 to 1.08GMR=GM ESRD/GM Healthy
SecondaryPart 1: Maximum Observed Plasma Concentration (Cmax) of MK-2060

Plasma samples were collected at pre-specified time points post-dose and Cmax was assessed.

Time frame:
Predose Day 1 and 1, 12, 24, 48, 52, 96, 168 hours postdose, then Days 12, 15, 22, 29, 60, 90, 120, 150
Reported as:
Geometric mean · nmol/Liter
Part 1: Maximum Observed Plasma Concentration (Cmax) of MK-2060
nmol/LiterPart 1: Panel A- MK-2060 (8 mg)Part 1: Panel A- MK-2060 (20 mg)Part 1: Panel A- MK-2060 (40 mg)
Part 1: Maximum Observed Plasma Concentration (Cmax) of MK-206014.8 ± 38.228.0 ± 49.361.3 ± 19.3
Statistical analysis
  • Part 1: Panel A- MK-2060 (8 mg) · Gmr: 1.11 · 90% CI 0.84 to 1.46GMR=GM ESRD/GM Healthy
  • Part 1: Panel A- MK-2060 (20 mg) · Gmr: 0.68 · 90% CI 0.52 to 0.87GMR=GM ESRD/GM Healthy
  • Part 1: Panel A- MK-2060 (40 mg) · Gmr: 0.78 · 90% CI 0.60 to 1.03GMR=GM ESRD/GM Healthy
SecondaryPart 1: Plasma Concentration of MK-2060 at 168 Hours (C168)

Plasma samples were collected at 168 hours post-dose and C168 was assessed.

Time frame:
168 hours post dose
Reported as:
Geometric mean · nmol/Liter
Part 1: Plasma Concentration of MK-2060 at 168 Hours (C168)
nmol/LiterPart 1: Panel A- MK-2060 (8 mg)Part 1: Panel A- MK-2060 (20 mg)Part 1: Panel A- MK-2060 (40 mg)
Part 1: Plasma Concentration of MK-2060 at 168 Hours (C168)6.29 ± 41.69.10 ± 57.715.8 ± 30.2
Statistical analysis
  • Part 1: Panel A- MK-2060 (8 mg) · Gmr: 1.50 · 90% CI 1.05 to 2.14GMR=GM ESRD/GM Healthy
  • Part 1: Panel A- MK-2060 (20 mg) · Gmr: 0.91 · 90% CI 0.67 to 1.25GMR=GM ESRD/GM Healthy
  • Part 1: Panel A- MK-2060 (40 mg) · Gmr: 0.86 · 90% CI 0.62 to 1.20GMR=GM ESRD/GM Healthy
SecondaryPart 1: Time to Maximum Observed Plasma Drug Concentration (Tmax) of MK-2060

Plasma samples were collected at pre-specified time points post-dose and Tmax was assessed.

Time frame:
Predose Day 1 and 1, 12, 24, 48, 52, 96, 168 hours postdose
Reported as:
Median · Hours
Part 1: Time to Maximum Observed Plasma Drug Concentration (Tmax) of MK-2060
HoursPart 1: Panel A- MK-2060 (8 mg)Part 1: Panel A- MK-2060 (20 mg)Part 1: Panel A- MK-2060 (40 mg)
Part 1: Time to Maximum Observed Plasma Drug Concentration (Tmax) of MK-20601.13 (0.75 to 12.00)0.97 (0.83 to 12.00)1.09 (0.90 to 12.00)
SecondaryPart 1: Plasma Elimination Terminal Half-life (t ½) of MK-2060

Plasma samples was collected at pre-specified time points post-dose and t ½ was assessed.

Time frame:
Predose Day 1 and 1, 12, 24, 48, 52, 96, 168 hours postdose
Reported as:
Geometric mean · Hours
Part 1: Plasma Elimination Terminal Half-life (t ½) of MK-2060
HoursPart 1: Panel A- MK-2060 (8 mg)Part 1: Panel A- MK-2060 (20 mg)Part 1: Panel A- MK-2060 (40 mg)
Part 1: Plasma Elimination Terminal Half-life (t ½) of MK-2060325 ± 88.5422 ± 69.0508 ± 21.7
SecondaryPart 1: Plasma Clearance (CL) of MK-2060

Plasma samples were collected at pre-specified time points post-dose and CL was assessed.

Time frame:
Predose Day 1 and 1, 12, 24, 48, 52, 96, 168 hours postdose
Reported as:
Geometric mean · Liters/hour
Part 1: Plasma Clearance (CL) of MK-2060
Liters/hourPart 1: Panel A- MK-2060 (8 mg)Part 1: Panel A- MK-2060 (20 mg)Part 1: Panel A- MK-2060 (40 mg)
Part 1: Plasma Clearance (CL) of MK-20600.0119 ± 61.20.0207 ± 63.40.0179 ± 31.7
SecondaryPart 1: Plasma Volume of Distribution (Vz) of MK-2060

Plasma samples were collected at pre-specified time points post-dose and Vz was assessed.

Time frame:
Predose Day 1 and 1, 12, 24, 48, 52, 96, 168 hours postdose
Reported as:
Geometric mean · Liters
Part 1: Plasma Volume of Distribution (Vz) of MK-2060
LitersPart 1: Panel A- MK-2060 (8 mg)Part 1: Panel A- MK-2060 (20 mg)Part 1: Panel A- MK-2060 (40 mg)
Part 1: Plasma Volume of Distribution (Vz) of MK-20605.56 ± 49.012.6 ± 65.313.1 ± 31.2
SecondaryPart 2: AUC0-168 of MK-2060

Plasma samples were collected at pre-specified time points post-dose and AUC0-168 hours was assessed.

Time frame:
Up to 168 hours on Day 1 and Day 22
Reported as:
Geometric mean · hr*nmol/L
Part 2: AUC0-168 of MK-2060
hr*nmol/LPart 2: MK-2060 25-mg Loading/ 25-mg Maintenance
Day 12290 ± 26.8
Day 229880 ± 28.9
SecondaryPart 2: Cmax of MK-2060

Plasma samples were collected at pre-specified time points post-dose and Cmax was assessed.

Time frame:
Day 1 and Day 22
Reported as:
Geometric mean · nmol/Liter
Part 2: Cmax of MK-2060
nmol/LiterPart 2: MK-2060 25-mg Loading/ 25-mg Maintenance
Day 132.6 ± 32.5
Day 2290.9 ± 30.4
SecondaryPart 2: C168 of MK-2060

Plasma samples were collected at 168 hours post-dose and C168 was assessed.

Time frame:
168 hours post dose on Days 1 and 22
Reported as:
Geometric mean · nmol/Liter
Part 2: C168 of MK-2060
nmol/LiterPart 2: MK-2060 25-mg Loading/ 25-mg Maintenance
Day 154.1 ± 42.1
Day 2243.8 ± 30.5
SecondaryPart 2: Tmax of MK-2060

Plasma samples were collected at pre-specified time points post-dose and Tmax was assessed.

Time frame:
Day 1 and Day 22
Reported as:
Median · Hours
Part 2: Tmax of MK-2060
HoursPart 2: MK-2060 25-mg Loading/ 25-mg Maintenance
Day 11.00 (0.92 to 47.92)
Day 221.00 (0.00 to 24.00)
SecondaryFold Change From Baseline in Activated Partial Thromboplastin Time (aPTT) of MK-2060: Part 1

Plasma samples were collected at pre-specified time points post-dose and aPTT values were assessed. The fold change (Day 8/Baseline) at Day 8 was reported.

Time frame:
Baseline and 168 hours post-dose (Day 8)
Reported as:
Number · Ratio
Fold Change From Baseline in Activated Partial Thromboplastin Time (aPTT) of MK-2060: Part 1
RatioPart 1: Panel A- MK-2060 (8 mg)Part 1: Panel A- MK-2060 (20 mg)Part 1: Panel C- MK-2060 (40 mg)Part 1: Placebo
Fold Change From Baseline in Activated Partial Thromboplastin Time (aPTT) of MK-2060: Part 11.04 (0.92 to 1.18)1.17 (1.06 to 1.30)1.52 (1.36 to 1.71)1.05 (0.92 to 1.19)
SecondaryFold Change From Baseline in aPTT of MK-2060: Part 2

Plasma samples were collected at pre-specified time points post-dose and aPTT values were assessed. The fold change (Day 8/Baseline) at Day 8 was reported.

Time frame:
Baseline and Day 8
Reported as:
Number · Ratio
Fold Change From Baseline in aPTT of MK-2060: Part 2
RatioPart 2: MK-2060 25-mg Loading/ 25-mg MaintenancePart 2: Placebo
Fold Change From Baseline in aPTT of MK-2060: Part 22.46 (1.95 to 3.11)0.68 (0.43 to 1.06)

Adverse events

Collected over Up to 164 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Panel A- MK-2060 (8 mg)0/6 (0%)0/6 (0%)1/6 (16.7%)
Part 1: Panel B- MK-2060 (20 mg)0/7 (0%)0/7 (0%)4/7 (57.1%)
Part 1: Panel C- MK-2060 (40 mg)0/6 (0%)1/6 (16.7%)3/6 (50%)
Part 1: Placebo0/5 (0%)0/5 (0%)3/5 (60%)
Part 2: MK-2060 25-mg Loading/ 25-mg Maintenance0/16 (0%)1/16 (6.3%)1/16 (6.3%)
Part 2: Placebo0/5 (0%)3/5 (60%)4/5 (80%)
Most frequent serious events
Most frequent serious events
EventPart 1: Panel A- MK-2060 (8 mg)Part 1: Panel B- MK-2060 (20 mg)Part 1: Panel C- MK-2060 (40 mg)Part 1: PlaceboPart 2: MK-2060 25-mg Loading/ 25-mg MaintenancePart 2: Placebo
Lower gastrointestinal haemorrhageGastrointestinal disorders0/60/70/60/50/161/5
PneumoniaInfections and infestations0/60/70/60/50/161/5
Arteriovenous graft thrombosisInjury, poisoning and procedural complications0/60/70/60/50/161/5
COVID-19Infections and infestations0/60/71/60/50/160/5
Myocardial infarctionCardiac disorders0/60/70/60/51/160/5
Most frequent other events
Showing 10 of 19
Most frequent other events
EventPart 1: Panel A- MK-2060 (8 mg)Part 1: Panel B- MK-2060 (20 mg)Part 1: Panel C- MK-2060 (40 mg)Part 1: PlaceboPart 2: MK-2060 25-mg Loading/ 25-mg MaintenancePart 2: Placebo
DiarrhoeaGastrointestinal disorders0/60/70/61/50/162/5
Back painMusculoskeletal and connective tissue disorders0/60/72/60/50/160/5
NauseaGastrointestinal disorders0/60/70/60/51/161/5
ToothacheGastrointestinal disorders0/60/70/61/50/160/5
COVID-19Infections and infestations0/60/70/60/50/161/5
Skin abrasionInjury, poisoning and procedural complications0/61/71/61/50/160/5
Thermal burnInjury, poisoning and procedural complications0/60/70/61/50/160/5
HeadacheNervous system disorders0/60/71/60/50/161/5
Arteriovenous fistula site haemorrhageInjury, poisoning and procedural complications0/60/71/60/50/160/5
SyncopeNervous system disorders0/60/71/60/50/160/5

Baseline characteristics

Seven participants in Part 1 also participated in Part 2. They have been removed from Part 2 listing and counted only once

Age, Continuous
Age, Continuous(Years)Part 1: Panel A- MK-2060 (8 mg)Part 1: Panel B- MK-2060 (20 mg)Part 1: Panel C- MK-2060 (40 mg)Part 1: PlaceboPart 2: MK-2060 25-mg Loading/ 25-mg MaintenancePart 2: PlaceboTotal
Mean56.8 ± 5.161.1 ± 4.358.2 ± 5.960.0 ± 7.354.7 ± 7.052.5 ± 11.657.2 ± 6.9
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Panel A- MK-2060 (8 mg)Part 1: Panel B- MK-2060 (20 mg)Part 1: Panel C- MK-2060 (40 mg)Part 1: PlaceboPart 2: MK-2060 25-mg Loading/ 25-mg MaintenancePart 2: PlaceboTotal
Female14212010
Male53448428
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Panel A- MK-2060 (8 mg)Part 1: Panel B- MK-2060 (20 mg)Part 1: Panel C- MK-2060 (40 mg)Part 1: PlaceboPart 2: MK-2060 25-mg Loading/ 25-mg MaintenancePart 2: PlaceboTotal
Hispanic or Latino0000101
Not Hispanic or Latino67658436
Unknown or Not Reported0000101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Panel A- MK-2060 (8 mg)Part 1: Panel B- MK-2060 (20 mg)Part 1: Panel C- MK-2060 (40 mg)Part 1: PlaceboPart 2: MK-2060 25-mg Loading/ 25-mg MaintenancePart 2: PlaceboTotal
American Indian or Alaska Native0000000
Asian0000000
Native Hawaiian or Other Pacific Islander0000000
Black or African American63338427
White04322011
More than one race0000000
Unknown or Not Reported0000000
08

Study locations

3 sites
  • Orlando Clinical Research Center ( Site 0002)
    Orlando, Florida 32809, United States
  • Prism Research ( Site 0003)
    Saint Paul, Minnesota 55114, United States
  • New Orleans Center for Clinical Research ( Site 0001)
    Knoxville, Tennessee 37920, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Dec 2021, 31 months.

Results were first posted in Jun 2024, 2 years 5 months after primary completion.

Of 46 industry-sponsored phase 1 interventional studies under Kidney Failure, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 31 months is above that.

Counting every sponsor, half of 67 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2019
First posted
Mar 13, 2019
StartActual
Apr 29, 2019
Primary completionActual
Dec 20, 2021
CompletionActual
Dec 20, 2021
Results first posted
Jun 6, 2024
Last update
Jun 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03873038
Responsible party
Sponsor
First posted
Mar 13, 2019
Start date
Apr 29, 2019
Primary completion
Dec 20, 2021
Completion
Dec 20, 2021
Results posted
Jun 6, 2024
Last update
Jun 6, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-2060

Start the discussion